No Data
No Data
Express News | D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
Express News | Hoth Therapeutics Announces Plans to Submit Expanded Access Application for Ht-001 to Support Cancer Patients in Need
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
Hoth Therapeutics Reports HT-001 Cream Efficacy in Case Study
Hoth Therapeutics Announces Results For HT-001
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to Be Presented at the American Academy of Dermatology 2025 Annual Meeting